EP2167061A1 - Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations - Google Patents
Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisationsInfo
- Publication number
- EP2167061A1 EP2167061A1 EP08805686A EP08805686A EP2167061A1 EP 2167061 A1 EP2167061 A1 EP 2167061A1 EP 08805686 A EP08805686 A EP 08805686A EP 08805686 A EP08805686 A EP 08805686A EP 2167061 A1 EP2167061 A1 EP 2167061A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- retinoid
- composition according
- rucinol
- weight
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 2
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000012641 Pigmentation disease Diseases 0.000 claims abstract description 15
- 230000019612 pigmentation Effects 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 230000032683 aging Effects 0.000 claims abstract description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 11
- -1 2-hydroxyethoxy Chemical group 0.000 claims description 10
- 208000003351 Melanosis Diseases 0.000 claims description 10
- 229960002916 adapalene Drugs 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- 206010014970 Ephelides Diseases 0.000 claims description 7
- 208000000069 hyperpigmentation Diseases 0.000 claims description 7
- 230000003810 hyperpigmentation Effects 0.000 claims description 7
- 229960003471 retinol Drugs 0.000 claims description 7
- 235000020944 retinol Nutrition 0.000 claims description 7
- 239000011607 retinol Substances 0.000 claims description 7
- 206010008570 Chloasma Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 claims description 5
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 3
- 238000005299 abrasion Methods 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 229960005280 isotretinoin Drugs 0.000 claims description 3
- 206010024217 lentigo Diseases 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 231100000760 phototoxic Toxicity 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960000565 tazarotene Drugs 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- OVMCYQMEOOZBKP-UHFFFAOYSA-N 4-[4-[4-(propan-2-ylamino)butoxy]-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)phenyl]benzoic acid Chemical compound C1=C(C=2C=C3C(C(CCC3(C)C)(C)C)=CC=2)C(OCCCCNC(C)C)=CC=C1C1=CC=C(C(O)=O)C=C1 OVMCYQMEOOZBKP-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims description 2
- 206010064127 Solar lentigo Diseases 0.000 claims description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 2
- 229960005339 acitretin Drugs 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 2
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000020945 retinal Nutrition 0.000 claims description 2
- 239000011604 retinal Substances 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 claims 1
- HLSHNXLMUMGCSV-UHFFFAOYSA-N 2-hydroxy-4-[3-hydroxy-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-ynyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)C#CC1=CC=C(C(O)=O)C(O)=C1 HLSHNXLMUMGCSV-UHFFFAOYSA-N 0.000 claims 1
- DGUXYDRSGSIRKZ-UHFFFAOYSA-N 4-[2-[3-tert-butyl-4-(diethylamino)phenyl]-2-hydroxyiminoethoxy]-2-hydroxybenzoic acid Chemical compound C1=C(C(C)(C)C)C(N(CC)CC)=CC=C1C(=NO)COC1=CC=C(C(O)=O)C(O)=C1 DGUXYDRSGSIRKZ-UHFFFAOYSA-N 0.000 claims 1
- 241000195940 Bryophyta Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims 1
- 229960002199 etretinate Drugs 0.000 claims 1
- 235000011929 mousse Nutrition 0.000 claims 1
- 230000021332 multicellular organism growth Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 208000031066 hyperpigmentation of the skin Diseases 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 25
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 230000035614 depigmentation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960000990 monobenzone Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000037370 skin discoloration Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- CCZCXFHJMKINPE-UHFFFAOYSA-N 2-phenylmethoxyphenol Chemical compound OC1=CC=CC=C1OCC1=CC=CC=C1 CCZCXFHJMKINPE-UHFFFAOYSA-N 0.000 description 1
- PUTQZOMYROSUPH-UHFFFAOYSA-N 4-[3-[4-(2-ethoxyethoxy)-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl]-3-hydroxyprop-1-ynyl]benzoic acid Chemical compound C=1C(C(CCC2(C)C)(C)C)=C2C(OCCOCC)=CC=1C(O)C#CC1=CC=C(C(O)=O)C=C1 PUTQZOMYROSUPH-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 201000010394 Ochronosis Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B23/00—Single-crystal growth by condensing evaporated or sublimed materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the invention relates to depigmenting compositions, methods for preparing such compositions, and their uses.
- the hyperpigmentation of the skin is a common disorder manifested by the appearance of brown or colored spots of the skin due to the accumulation of melanin, and conferring on the skin a heterogeneity. Pigmented spots can appear on all parts of the body, especially on the backs of hands, on the face, beaulleté and skull of men.
- age spots or solar lentigines are a common form of hyperpigmentation. They are due to sun damage, and usually appear on the back of the hands and arms, on the neckline or at the level of the face. These spots are darker than freckles or ephelides, and persist in winter. Therefore, there is a real need for an effective and safe treatment of the symptoms of photoaging, especially hyperpigmentary tasks induced by exposure to ultraviolet light.
- Melasma or chloasma lesions are more extensive than age spots and localized on the face. They are most often due to hormonal changes. Pregnancy, for example, can trigger the overproduction of melanin that causes the "pregnancy mask".
- Skin color changes can result from external causes, such as skin diseases such as acne, or skin lesions. Freckles are also small brown spots that can appear anywhere on the body, but are the most common on the face and arms. Freckles are an inherited feature.
- Post-inflammatory hyperpigmentation is also a disorder of frequent pigmentation that may be the consequence of various skin disorders as well as therapeutic interventions. This excess skin discoloration may be due to infections, allergic reactions, trauma such as abrasion, scarring, burning, drug reactions, phototoxic eruptions, and also following inflammatory diseases such as acne, eczema, psoriasis, lichen planus, lupus erythematosus, atopic dermatitis, or cutaneous lymphoma.
- PIHP is more common in dark phototypes such as non-Caucasian skin, especially Asian, black, or mixed skin
- Depigmenting agents or bleaching agents currently used in the form of topical compositions make it possible to reduce the density of melanin in the epidermis. These agents are usually absorbed through the lower layers of the epidermis and slow down the formation of melanin.
- Hydroquinone is a depigmenting agent, as well as its derivatives, such as benzyl-oxy-phenol and hydroquinone monobenzylether.
- these agents have several drawbacks: the hydroquinone is unstable in an alkaline medium and is oxidized in the form of quinone, which gives a brownish color to the compositions comprising it; hydroquinone is irritating; it can also induce hypersensitivity reactions and in rare cases ochronoses; hydroquinone is also suspected to be carcinogenic; hydroquinone monobenzylether is not metabolized properly when absorbed through the skin and causes irreversible depigmentation.
- Methoxyphenol, a hydroquinone ether which has the disadvantage of being poorly soluble in water and difficult to incorporate in cosmetic or dermatological formulations, is also known.
- depigmenting composition comprising (US Pat. No. 3,856,934) hydroquinone, retinoic acid and dexamethasone, but this composition is also irritating and can cause itching in the most extreme cases.
- Various vitamin C-type products, fruit acids, and sunscreens have been developed to treat these pigmentation problems, but most of them contain unstable mixtures and are not very active.
- the pallor or whiteness of the Asian face is obtained with molecules, such as arbutin, kojic acid, or ascorbic acid, which may be poorly tolerated or irritating.
- compositions having a depigmenting or lightening activity and which are well tolerated by the skin especially for non-Caucasian skin, such as Hispanic, Indian, black, Asian or mixed skin.
- Rucinol or lucinol, or 4-butyl-resorcinol, is marketed as a lightening agent for brown spots related to pigmentation disorders.
- a problem to be solved by the invention is to provide a composition which shows an improved efficiency in the cosmetic and / or dermatological treatment of pigmentation, without the disadvantages of the compositions of the prior art.
- the invention firstly relates to a composition, preferably dermatological or cosmetic, characterized in that it comprises, in a medium physiologically acceptable, (i) at least one compound selected from rucinol and its salts and (ii) at least one retinoid (hereinafter referred to as "active (i) and (ii)").
- dermatological composition is meant a composition for treating and / or preventing skin pigment disorders.
- cosmetic composition is meant a composition intended to beautify the skin and / or improve its physical appearance.
- physiologically acceptable medium is meant a medium compatible with the skin, mucous membranes and / or integuments.
- It has the second object the use of at least one compound selected from rucinol and its salts, and at least one retinoid, to prepare a drug for the treatment and / or prevention of disorders of pigmentation. It also relates to the use of a composition comprising, in a physiologically acceptable medium, at least one compound chosen from rucinol and its salts, and at least one retinoid, for preparing a medicinal product intended for treatment and / or for prevention of disorders of pigmentation.
- Its third object is the use of a cosmetic composition
- a cosmetic composition comprising, in a physiologically acceptable medium, at least one compound chosen from rucinol and its salts, and further comprising a retinoid, for the prevention and / or cosmetic treatment of skin pigmentation.
- It also relates to a method for dermatological or cosmetic treatment of cutaneous pigmentation, comprising the administration of a composition according to the invention to an individual to be treated.
- Rucinol or lucmol, or 4-butyl-resorcinol, is a compound of formula:
- rucinol salts is intended especially to mean salts formed with a pharmaceutically acceptable base, in particular a mineral base such as sodium hydroxide, potassium hydroxide and aqueous ammonia, or an organic base such as lysine, arginine, N-methyl- glucamine, but also the salts formed with fatty amines such as dioctylamine, ammomethyl propanol and stearylamine.
- a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide and aqueous ammonia
- organic base such as lysine, arginine, N-methyl- glucamine
- fatty amines such as dioctylamine, ammomethyl propanol and stearylamine.
- rucinol will be used.
- the Applicant has demonstrated a significant improvement in the depigmenting activity of rucinol when it is in combination with a retinoid and, in particular, a faster depigmentation than the compositions of the prior art and that rucinol alone .
- an effective amount of retinoid acts in synergy with an effective amount of rucinol for the depigmenting effect of the skin and can significantly reduce side effects such as irritation.
- Retinoids find various applications in dermatology. However, it is known that these compounds have significant undesirable side effects, whether used systemically or topically. They cause in particular strong irritations. These disadvantages of retinoids did not allow to expect the advantageous effects of the compositions according to the invention.
- the retinoids that can be used in the context of the invention include, in particular, all-trans retinoic acid or tretinoin, 13-cis-retinoic acid or isotretinoin acid, acitretin, arotinoic acid, retinol, and adapalene.
- compositions according to the invention or the active agents (i) and (li) thus make it possible to reduce cutaneous pigmentation, and in particular local hyperpigmentations of the skin. In particular, when they are used topically, they produce a depigmentation of the cutaneous zone on which they are applied.
- depigmentation is meant to obtain a discoloration of a pigmented skin area.
- “depigmentation” is meant to obtain a discoloration of said zone until a color similar to that of the neighboring skin is obtained.
- compositions of the invention or the active agents (i) and (ii) are particularly suitable for the treatment and / or prevention of pigmentation disorders such as: melasma or chloasma, lentigines, senile lentigo,
- - post-inflammatory hyperpigmentations particularly due to infections, allergic reactions, traumatic injuries (such as abrasions, scars, burns), reactions to drugs, phototoxic eruptions, and also following inflammatory skin diseases (such as acne, eczema, psoriasis, rosacea, lichen planus, lupus erythematosus, atopic dermatitis, and cutaneous lymphoma);
- compositions according to the invention or the active ingredients (i) and (ii) also find application in the cosmetic field, in particular in the protection against the harmful aspects of the sun, for preventing and / or for combating photo-induced aging. or chronological of the skin and integuments.
- the invention also relates to a non-therapeutic cosmetic treatment method for embellishing the skin and / or improving its surface appearance, comprising applying to the skin and / or its integuments a composition comprising at least a compound selected from rucinol and its salts, and at least one retinoid.
- the compositions according to the invention advantageously comprise between 0.0001 and 20% by weight of at least one retinoid and between 0.0001 and 20% by weight of at least one compound chosen from rucinol and its salts. , relative to the total weight of the composition.
- they comprise between 0.001 and 10% of at least one retinoid and between 0.01 and 15% of rucinol, or its salts, and more preferentially between 0.1 and 5% by weight of at least one retinoid and between 0.1 and 5% by weight of at least one compound chosen from rucinol and its salts, relative to the total weight of the composition.
- compositions of the invention may furthermore comprise any additive usually used in the pharmaceutical, dermatological or cosmetic field compatible with rucinol or its salts and a retinoid.
- perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, soothing and protective agents for the skin such as allantoin, propenetrating agents, gelling agents or a mixture of those -this.
- additives may be present in the composition in an amount of from 0 to 20% by weight relative to the total weight of the composition.
- sequestering agents examples include ethylene diamine tetracetic acid (EDTA), as well as its derivatives or its salts, dihydroxyethylglycine, citric acid, tartaric acid, or mixtures thereof.
- EDTA ethylene diamine tetracetic acid
- preservatives examples include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinyl urea, parabens, or mixtures thereof.
- humectants examples include glycerin and sorbitol.
- compositions of the invention are capable of containing one or more propenetrating agents in preferential concentrations ranging from 0 to 20% and more preferentially ranging from 0.6 to 3% by weight relative to the total weight of the composition.
- propenetrating agents it is preferable to use, without this list being limiting, compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol and ethoxydiglycol.
- compositions according to the invention may also contain one or more surfactants in preferential concentrations ranging from 0 to 10% and more preferentially ranging from 0.1 to 2% by weight of the total weight.
- Administration may be topical, enteral or oral, parenteral or ocular.
- topical route is particularly preferred.
- Topically we mean an application on the skin and / or the mucous membranes.
- compositions of the present invention may be in any of the galenical forms normally used for topical application, especially in liquid, pasty or solid form, and more particularly in the form of ointments, aqueous, hydroalcoholic or oily solutions, dispersions lotion-type, aqueous, anhydrous or lipophilic gels, powders, soaked swabs, syndets, wipes, sprays, patches, foams, sticks, shampoos, compresses, washing bases, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (oil in water) or conversely (water in oil), or suspensions or emulsions of soft, semi-liquid or solid type cream, gel or ointment.
- aqueous, hydroalcoholic or oily solutions dispersions lotion-type, aqueous, anhydrous or lipophilic gels, powders, soaked swabs, syndets, wipes, sprays, patches,
- This topical composition may be in anhydrous form, in aqueous form or in the form of an emulsion or else microemulsions, microcapsules, microparticles or vesicular dispersions of ionic and / or non-ionic type. ionic.
- the composition is in the form of an ointment, a cream, a lotion or a gel.
- the aqueous phase of a composition according to the invention in the form of an emulsion may comprise water, a floral water such as cornflower water, or a natural thermal or mineral water, for example chosen from the water of Vittel, the waters of the Vichy basin, the water of Uriage, the water of the Roche Posay, the water of the Bourboule, the water of Enghien-les-Bains, the water of Saint Gervais-les-Bains, the water of Néris-les-Bains, the water of Allevard-les-Bains, the water of Digne, the water of Maizines, the water of Neyrac-les-Bains, the water of Lons-le-Saunier, the Good Waters, the water of Rochefort, the water of Saint Christau, the water of the Fumades and the water of Tercis-les-bains, the water of Avène or the water of Aix les Bains.
- Said aqueous phase may be present at a content of between 10 and
- composition according to the invention may contain a gelling agent with preferential concentrations ranging from 0.1 to 15% and, more preferably, from 0.5 to 5%.
- gelling agents of the polyacrylamide family such as the mixture Sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 sold under the name Simulgel TM 600 by the company
- Seppic TM the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture, for example that sold under the name Sepigel 305 TM by the company Seppic TM, the family of acrylic polymers coupled to hydrophobic chains such as the
- modified starches such as modified potato starch sold under the name Solanace TM Structure or mixtures thereof.
- Silicone oil (“Abil 300.000 is” sold by GOLDSCHMIDT) qs 100 g
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0754886A FR2915682B1 (fr) | 2007-05-04 | 2007-05-04 | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
PCT/FR2008/050731 WO2008148968A1 (fr) | 2007-05-04 | 2008-04-22 | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2167061A1 true EP2167061A1 (fr) | 2010-03-31 |
Family
ID=38800746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08805686A Withdrawn EP2167061A1 (fr) | 2007-05-04 | 2008-04-22 | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
Country Status (12)
Country | Link |
---|---|
US (2) | US20100143445A1 (ja) |
EP (1) | EP2167061A1 (ja) |
JP (1) | JP2010526124A (ja) |
KR (1) | KR20100016204A (ja) |
CN (1) | CN101674818A (ja) |
AU (1) | AU2008259754A1 (ja) |
BR (1) | BRPI0809880A2 (ja) |
CA (1) | CA2685482A1 (ja) |
FR (1) | FR2915682B1 (ja) |
MX (1) | MX2009011743A (ja) |
RU (1) | RU2009144988A (ja) |
WO (1) | WO2008148968A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141237B2 (en) | 2003-01-24 | 2006-11-28 | Connetics Australia Pty Ltd. | Pharmaceutical foam |
FR2910321B1 (fr) | 2006-12-21 | 2009-07-10 | Galderma Res & Dev S N C Snc | Gel creme comprenant au moins un retinoide et du peroxyde de benzole |
FR2910320B1 (fr) | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | Emulsion comprenant au moins un retinoide et du peroxyde de benzole |
FR2931662B1 (fr) * | 2008-05-30 | 2010-07-30 | Galderma Res & Dev | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise. |
FR2931661B1 (fr) * | 2008-05-30 | 2010-07-30 | Galderma Res & Dev | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide. |
FR2931663B1 (fr) * | 2008-05-30 | 2010-07-30 | Galderma Res & Dev | Nouvelles compositions depigmentantes anhydre comprenant un derive phenolique solubilise. |
CA2723313A1 (fr) * | 2008-05-30 | 2009-12-30 | Galderma Research & Development | Compositions depigmentantes anhydres comprenant, au sein de la phase grasse un derive phenolique solubilise et un retinoide |
PL2400951T3 (pl) | 2009-02-25 | 2019-02-28 | Mayne Pharma Llc | Miejscowa kompozycja pianki |
DE102009048970A1 (de) * | 2009-10-09 | 2011-04-14 | Beiersdorf Ag | Verwendung von 4-n Butylresorcin zur Herstellung einer kosmetischen oder dermatologischen Zubereitung zur Prophylaxe oder Behandlung von Augenringen die durch eine gestörte Durchblutung der Haut im Augenbereich hervorgerufen werden |
CN101791282B (zh) * | 2009-12-29 | 2013-09-25 | 广东药学院 | 一种美容换肤液及其制备方法和应用 |
CN101961299B (zh) * | 2010-09-28 | 2014-04-02 | 清华大学 | 一种中草药凝胶化妆品及其制备方法 |
FR2969492B1 (fr) * | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene |
FR2991180B1 (fr) * | 2012-06-01 | 2014-06-13 | Galderma Res & Dev | Compositions topiques de type emulsion sans emulsionnant a base de particules stabilisantes. |
FR2991172A1 (fr) * | 2012-06-01 | 2013-12-06 | Galderma Res & Dev | Compositions pharmaceutiques topiques comprenant des microcapsules |
FR2991176B1 (fr) * | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions topiques, contenant un retinoide solubilise, de type gel hydroglycolique |
FR2991174B1 (fr) * | 2012-06-01 | 2014-12-26 | Galderma Res & Dev | Composition dermatologique comprenant des oleosomes et des retinoides, son procede de preparation et son utilisation |
FR2991177B1 (fr) * | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant |
FR2991175B1 (fr) * | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions pharmaceutiques topiques de type emulsion h/e contenant un retinoide |
US11324679B2 (en) | 2016-05-12 | 2022-05-10 | Conopco, Inc. | Method for stabilizing retinoic acid precursors and a skin benefit composition with stabilized retinoic acid precursors |
WO2019011619A1 (en) * | 2017-07-12 | 2019-01-17 | Unilever Plc | REINFORCING OIL FOR SKIN CARE COMPOSITION |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0651619B2 (ja) * | 1988-05-09 | 1994-07-06 | 株式会社クラレ | 美白剤 |
FR2723315B1 (fr) * | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
JP2001206813A (ja) * | 2000-01-27 | 2001-07-31 | Pola Chem Ind Inc | 物理的治療用の皮膚外用剤 |
US20030003142A1 (en) * | 2001-05-23 | 2003-01-02 | Wortzman Mitchell S. | Composition and method for the treatment of pigmentation disorders |
AU2003270272B2 (en) * | 2002-09-05 | 2008-06-19 | Galderma Research & Development, S.N.C. | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
JP2006510652A (ja) * | 2002-12-12 | 2006-03-30 | ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ | フェノール誘導体およびレチノイド含有水−アルコール脱色ゲル |
CN100496452C (zh) * | 2003-12-15 | 2009-06-10 | 可乐丽股份有限公司 | 皮肤外用剂 |
FR2871377B1 (fr) * | 2004-06-11 | 2007-08-24 | Galderma Res & Dev | Gel depigmentant hydroalcoolique comprenant du mequinol et de l'adapalene |
AU2005318292B2 (en) * | 2004-12-23 | 2011-09-22 | Galderma Research & Development | Novel ligands that modulate RAR receptors, and use thereof in human medicine and in cosmetics |
FR2889662B1 (fr) * | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
-
2007
- 2007-05-04 FR FR0754886A patent/FR2915682B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-22 JP JP2010506973A patent/JP2010526124A/ja active Pending
- 2008-04-22 WO PCT/FR2008/050731 patent/WO2008148968A1/fr active Application Filing
- 2008-04-22 CA CA002685482A patent/CA2685482A1/fr not_active Abandoned
- 2008-04-22 CN CN200880014227A patent/CN101674818A/zh active Pending
- 2008-04-22 AU AU2008259754A patent/AU2008259754A1/en not_active Abandoned
- 2008-04-22 BR BRPI0809880-8A patent/BRPI0809880A2/pt not_active IP Right Cessation
- 2008-04-22 RU RU2009144988/15A patent/RU2009144988A/ru not_active Application Discontinuation
- 2008-04-22 EP EP08805686A patent/EP2167061A1/fr not_active Withdrawn
- 2008-04-22 KR KR1020097023026A patent/KR20100016204A/ko not_active Application Discontinuation
- 2008-04-22 MX MX2009011743A patent/MX2009011743A/es not_active Application Discontinuation
-
2009
- 2009-11-04 US US12/588,972 patent/US20100143445A1/en not_active Abandoned
-
2012
- 2012-07-17 US US13/551,437 patent/US20120282314A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2008148968A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20100143445A1 (en) | 2010-06-10 |
RU2009144988A (ru) | 2011-06-10 |
MX2009011743A (es) | 2009-11-11 |
WO2008148968A1 (fr) | 2008-12-11 |
BRPI0809880A2 (pt) | 2014-09-30 |
CN101674818A (zh) | 2010-03-17 |
FR2915682A1 (fr) | 2008-11-07 |
KR20100016204A (ko) | 2010-02-12 |
US20120282314A1 (en) | 2012-11-08 |
CA2685482A1 (fr) | 2008-12-11 |
FR2915682B1 (fr) | 2009-07-03 |
AU2008259754A1 (en) | 2008-12-11 |
JP2010526124A (ja) | 2010-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2167061A1 (fr) | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations | |
EP2144590B1 (en) | Skin treatment compositions and methods | |
EP0749752B1 (fr) | Utilisation de ligands spécifiques des récepteurs RXRs | |
EP0892633B1 (fr) | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v. | |
EP0694301A1 (fr) | Mélange synergétique d'au moins un ligand spécifique des RXRs et au moins un ligand spécifique de RAR-alpha | |
FR2946249A1 (fr) | Compositions topiques depigmentantes, et leurs utilisations. | |
CA2578121A1 (fr) | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee | |
WO2005060948A1 (fr) | Utilisation du fepradinol pour la preparation d’une composition pharmaceutique pour le traitement de la rosacee | |
FR2894141A1 (fr) | Composition depigmentante de la peau compreant un derive d'acide naphtoique | |
EP1718296A2 (fr) | Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap | |
Patel | FACIAL MELANOSES-HYPERPIGMENTARY DISORDERS | |
EP1686978B1 (fr) | Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
WO2005060962A1 (fr) | Utilisation du piketoprofen pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
EP1732542A2 (fr) | Utilisation du metronidazole pour le traitement d'un desordre de la vascularisaton cutanee | |
FR2946250A1 (fr) | Compositions topiques depigmentantes, et leurs utilisations. | |
WO2002074277A1 (fr) | Composition dermatologique a base de glabridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20120518 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120929 |